Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 2, 2002 - Issue 2
Submit an article Journal homepage
63
Views
12
CrossRef citations to date
0
Altmetric
Review

Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson’s disease

Miika Linna National Research and Development Center for Welfare and Health, Helsinki, Finland. [email protected]
,
Eeva Taimela Orion Pharma Research Centre, Espoo, Finland. [email protected]
,
Marjo Apajasalo Orion Pharma Research Centre, Espoo, Finland. [email protected]
&
Reijo J Marttila Turku University Central Hospital, Turku, Finland. [email protected]
Pages 91-97 | Published online: 09 Jan 2014

References

  • Buxton M, Drummond M, VanHout B et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ. 6, 217–227 (1997).
  • Briggs A, Fenn P Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. 7, 723–740 (1998).
  • Stinnett A, Mullahy J. Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Merl Decis. Making18, s68—s80 (1998).
  • Brennan A, Akehurst R. Modelling in health economic evaluation. What it is place? What is its value? PharmacoEconomics17 (5), 445–459 (2000).
  • Briggs A. Handling uncertainty in cost- effectiveness models. PharmacoEconomics 17(5), 479–500 (2000).
  • Hjelmgren J, Berggren F, Andersson E Health economic guidelines - similarities, differences and some implications. Value in Health 4(3), 225–250 (2001).
  • Lang A, Lozano A. Parkinson's disease. First of two parts. N. Engl. Med 339(15), 1044–1053 (1998).
  • Lang A, Lozano A. Parkinson's disease. Second of two parts. N Engl. I Merl 339(16), 1130–1143 (1998).
  • Kuopio AM, Marttila RJ, Helenius H, Rinne UK. Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology 52 (2), 302–308 (1999).
  • Jenkinson C, Fitzpatrick R, Peto V Health- related quality-of-life measurement in patients with Parkinson's disease. PharmacoEconomics 15, 157–165 (1999).
  • Carter JH, Stewart BJ, Archbold PG et al Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's Study Group. May. Disord 13(1), 20–28 (1998).
  • Karlsen IKH, Larsen JP, Tandberg E, Maeland JG. Quality of life measurements in patients with Parkinson's disease: a community based study. Eur Ailtrology5,1–8 (1998).
  • Kuopio AM, Marttila RJ, Helenius H, Toivonen M, Rinne UK. The quality of life in Parkinson's disease. May. Disaml. 15(2), 216–223 (2000).
  • Chrischilles E, Rubenstein L, Voelker M, Wallace R, Rodnizky R. The health burdens of Parkinson's disease. May. Disord. 13(3), 406–413 (1998).
  • Dodel R, Singer M, Köhne-Volland R. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. PharmacoEconomics 14(3), 299–312 (1998).
  • Rubenstein LM, Chrischilles EA, Voelker MD. The impact of Parkinson's disease on health status, health expenditures, and productivity, estimates from the national medical expenditure survey. PhatmacoEconomics 12(4), 486–498 (1997).
  • Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family, and the individual. jAm. Geriatric Soc. 45(7), 844–849 (1997).
  • LePen C, Wait S, Moutard-Martin F, Dujardin M, Ziegler M. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. PhatmacoEconomics16(1), 59–69 (1999).
  • Mennistö P, Kaakkola S. Cathecol-O- methyltransferase (COMT): biochemistry, molecular biology, pharmacology and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51(4), 593–628 (1999).
  • Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann. Neural. 42(5), 747–755 (1997).
  • Rinne UK, Larsen JP, Siden A, Worm- Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51(5), 1309–1314 (1998).
  • Nuijten M, VanIperen P, Palmer C, VanHilten B, Snyder E. Cost-Effectiveness Analysis of Entacapone in Parkinson's Disease: a Markov process analysis. Value in Health 4(4), 316–328 (2001).
  • Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology17 (5), 427–442 (1967).
  • Hoehn MM. The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neural. Gun. 10(2), 331–339 (1992).
  • Kerenen T, Kaakkola S, Sotaniemi K, EcoPD Study Group. Economic burden and quality of life impairment increase with severity of PD. Submitted. (2002).
  • Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann. Med. 33(5), 328–336 (2001).
  • Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med. Decis. Making13(4), 322–338 (1993).
  • Briggs A, Sculpher M. An Introduction to Markov modelling for economic evaluation. PharmacoEconomics 13 (4), 397–409 (1998).
  • Palmer C, Nuijten M, Schmier J, Subedi P, Snyder E. The cost-effectiveness of treatment with entacapone for patients with Parkinson's disease in the United States. Parkit2sonism Related Disold 7,S106 (2001).
  • Doubilet P, Begg C, Weinstein M. Probabilistic sensitivity analysis using Monte Carlo simulation. Med. Decis. Making5, 157–177 (1985).
  • TreeAge Software. Decision Analysis by TreeAge (DATA). Williamstown, MA, USA (2001).
  • Sendi P, Clemen R. Sensitivity analysis on a chance node with more than two branches. Med. Decis. Making19,499–502 (1999).
  • Halpern E, Weistein M, Hunink M, Gazelle G. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med. Decis. Making 20,314–322 (2000).
  • Siderowf A, Holloway O, Stern M. Cost- effectiveness analysis in Parkinson's disease. May. Disord. 15(3), 439–445 (2000).
  • Willan AR, O'Brien BJ, Leyva RA. Cost- effectiveness analysis when the WTA is greater than the WTP. Stat. Med. 20(21), 3251–3259 (2001).
  • Willan AR, Lin DY. Incremental net benefit in randomized clinical trials. Stat. Med. 20(11), 1563–1574 (2001).
  • O'Hagan A, Stevens J, Montmartin J. Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. PharmacoEconomics17 (4), 339–348 (2000).
  • O'Hagan A, Stevens J, Montmartin J. Bayesian cost-effectiveness analysis from clinical trial data. Stat. Med. 20,733–753 (2001).
  • Olanow C, Watts R, Koller W An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines. Neumlogy56, 1S-88S (2001).
  • Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 59(6), 1233–1250 (2000).
  • Olanow C, Obeso J. The role of COMT inhibitors in the treatment of Parkinson's disease. Neumlogy55, S1—S81 (2000).
  • Dodel RC, Berger K, Oertel WH. Health- related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. PharmacoEconomics 19(10), 1013–1038 (2001).
  • Nuijten M, Hadjadjeba L, Evans C, van den Berg J. Cost effectiveness of fluvoxamine in the treatment of recurrent depression in France. PharmacoEconomics 14(4), 433–445 (1998).
  • Obenchain R, Melfi C, Croghan T, Bueshing D. Bootstrap analyses of cost effectiveness in antidepressant pharmacotherapy. PhatmacoEconomics11, 464–472 (1997).
  • Pasta D, Taylor J, Henning J. Probabilistic sensitivity analysis incorporating the bootstrap: an example comparing treatments for the eradication of Helicobacter Pylori. Med. Decis. Making 19,353–363 (1999).
  • Chancellor JV, Hill AM, Sabin CA, Simpson KN, Youle M. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. PharmacoEconomic512(1), 54–66 (1997).
  • O'Hagan A, Stevens J. A framework for cost-effectiveness analysis from clinical trial data. Health Econ. 10,303–315 (2001).
  • Claxton K. Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Health Econ. 8,269-274 (1999). Website

Websites

  • http:\\chpe.buseco.monash.edu.au click Publications: Working papers 41 and 42. Affiliations

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.